Search Results

Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis.

• Authors : Marciniec K; Department of Organic Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jagiellońska 4, 41-200, Sosnowiec, Poland.; Beberok A

Subjects: COVID-19 Drug Treatment*; Ciprofloxacin/Ciprofloxacin/Ciprofloxacin/*pharmacology ; Coronavirus 3C Proteases/Coronavirus 3C Proteases/Coronavirus 3C Proteases/*drug effects

• Source: Pharmacological reports : PR [Pharmacol Rep] 2020 Dec; Vol. 72 (6), pp. 1553-1561. Date of Electronic Publication: 2020 Oct 15.Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101234999 Publication Model: Print-Electronic Cited Medium:

Record details

An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.

• Authors : Bennett AC; Department of Clinical Pharmacy and Outcomes Sciences, The University of South Carolina College of Pharmacy , Columbia , SC , USA.; Bennett CL

Subjects: Ciprofloxacin/Ciprofloxacin/Ciprofloxacin/*adverse effects ; Levofloxacin/Levofloxacin/Levofloxacin/*adverse effects ; Moxifloxacin/Moxifloxacin/Moxifloxacin/*adverse effects

• Source: Expert opinion on drug safety [Expert Opin Drug Saf] 2019 Nov; Vol. 18 (11), pp. 1055-1063. Date of Electronic Publication: 2019 Sep 18.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Development and validation of a UPLC-MS/MS method for simultaneous quantification of levofloxacin, ciprofloxacin, moxifloxacin and rifampicin in human plasma: Application to the therapeutic drug monitoring in osteoarticular infections.

• Authors : LLopis B; AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, F-75013 Paris, France.; Funck-Brentano C

Subjects: Chromatography, High Pressure Liquid/Chromatography, High Pressure Liquid/Chromatography, High Pressure Liquid/*methods ; Ciprofloxacin/Ciprofloxacin/Ciprofloxacin/*blood ; Levofloxacin/Levofloxacin/Levofloxacin/*blood

• Source: Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2020 May 10; Vol. 183, pp. 113137. Date of Electronic Publication: 2020 Feb 01.Publisher: Elsevier Science Country of Publication: England NLM ID: 8309336 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Ciprofloxacin Corneal Deposits With Complete Dissipation After Switching to Moxifloxacin.

• Authors : Quan AV; Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida.; Huang AM

Subjects: Chemical Precipitation*; Ciprofloxacin/Ciprofloxacin/Ciprofloxacin/*adverse effects ; Cornea/Cornea/Cornea/*drug effects

• Source: JAMA ophthalmology [JAMA Ophthalmol] 2020 Mar 01; Vol. 138 (3), pp. e190921. Date of Electronic Publication: 2020 Mar 12.Publisher: American Medical Association Country of Publication: United States NLM ID: 101589539 Publication Model: Print-Electronic Cited Medium:

Record details

Comparing Oral Moxifloxacin and Ciprofloxacin Ear Drops Versus Ciprofloxacin Ear Drops Only in Patients with Active Mucosal Chronic Otitis Media.

• Authors : Khan, Amir Ali; Asim, Muhammad Umar; Rehman, Syed Tehmina

Subjects: OTITIS media; MOXIFLOXACIN; CIPROFLOXACIN

• Source: Pakistan Armed Forces Medical Journal. Jun2022, Vol. 72 Issue 3, p948-951. 4p.

Record details

Increasing resistance to fluoroquinolones among Haemophilus species in Southern Taiwan.

• Authors : Chang CM; Division of Infectious Diseases, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan; Division of Geriatrics and Gerontology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan

Subjects: Anti-Bacterial Agents/Anti-Bacterial Agents/Anti-Bacterial Agents/*therapeutic use ; Ciprofloxacin/Ciprofloxacin/Ciprofloxacin/*therapeutic use ; Haemophilus influenzae/Haemophilus influenzae/Haemophilus influenzae/*drug effects

• Source: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi [J Microbiol Immunol Infect] 2017 Apr; Vol. 50 (2), pp. 258-260. Date of Electronic Publication: Publisher: published by Elsevier for the Taiwan Society of Microbiology Country of Publication: England NLM ID: 100956211 Publication Model: Print-Electronic

Record details

Moxifloxacin Solution For Infusions, 400 Mg/250 Ml, 250 Ml Each; Ciprofloxacin Solution For Infusions, 2 Mg/ml Per 100 Ml; Imipenem 500mg And Celastatin 500mg Powder For Solution For Infusion Bottle #.

• Source: Mena Report. 2024.

Record details

Ciprofloxacin/levofloxacin/moxifloxacin: Various toxicities: 9 case reports.

Subjects: *MOXIFLOXACIN; *CIPROFLOXACIN

• Source: Reactions Weekly. 10/28/2023, Vol. 1980 Issue 1, p124-124. 1p.

Record details

Agricola

Record details

Agricola

Record details